Full-Time

Neuroscience Sales Representative

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$79k - $130k/yr

+ Commission

Redding, CA, USA + 2 more

More locations: Reno, NV, USA | Chico, CA, USA

Hybrid

Some overnight travel may be required; occasional travel to corporate HQ and training/sales meetings.

Category
Sales & Account Management (1)
Required Skills
Data Analysis
Requirements
  • Must have Bachelor’s degree from an accredited college or university as well as a valid driver’s license and safe driving record.
  • Must have 1+ years of documented success in B2B sales experience required; previous sales experience in pharmaceuticals, biologics, and/or medical device sales preferred
  • Antipsychotic, and/or bi-polar sales experience is a plus
  • Must have strong desire and passion for improving the lives of patients and their caregivers. Ideal candidate emulates patient-centricity.
  • Must act with high integrity and always in accordance with the Company’s Compliance policies and procedures.
  • Must have strong sense of self-motivation, initiative, and entrepreneurial thirst, excellent decision-making judgment, strong teaming/collaboration and cross-functional skills.
  • A proven track record of success in learning and adapting to an evolving environment such as Covid-19 in order to overcome obstacles and challenges.
  • Must have ability to be agile and adapt to the changing telemedicine/virtual environment.
  • Ability to analyze data/metrics to assess progress against objectives as well as diagnose performance issues and identify new opportunities.
  • Must have strong verbal, presentation, and listening skills.
  • Experience establishing new customer relationships and communicating technical information to a diverse customer audience.
  • Work hours may include meetings scheduled outside of normal working hours.
  • Territories may require some overnight travel depending on geography.
  • Some domestic travel to corporate headquarters, training and sales meetings will also be required on a periodic basis.
  • Must be able to perform all essential functions of the position, with or without reasonable accommodation.
Responsibilities
  • Following compliance guidelines, drives sales performance to ensure sales forecasts are met or exceeded within assigned territory by calling on predominantly Primary Care Health Care Professionals offices and select primary care targets within both in-person and virtually.
  • Develop superior product and disease state knowledge and effectively educate and engage healthcare professionals in dialogue about clinical evidence, approved indications, and product efficacy/safety profiles to support on-label prescribing for appropriate patients.
  • Effectively uses assigned budgets to achieve territory objectives. Customizes discussions and client interactions based on customer’s needs in a compliant and ethical manner.
  • Function independently with sales proficiency to drive sales performance and ensure sales forecasts and assigned budgets meet or exceed therapeutic and territory expectations.
  • Maintains current understanding of local market, practice structures, evolving customers, and key influencers. Routinely shares such information with relevant internal Intra-Cellular stakeholders.
  • Provides input into resource allocation decisions across customers/region. Identifies and selects programs/resources available and appropriate for each customer, practice, and/or system.
  • Provides special education to healthcare providers through appropriate programs that fall within ITCI’s ethical guidelines.
  • Works with District Manager and key stakeholders to develop a local business plan that ensures achievement of all business objectives. Capitalizes on formulary approvals and other business opportunities through effective implementation of the strategic plan.
  • Collaborates with other Neuroscience Sales Specialist-II’s on common objectives and sharing of best practices.
  • Accountable for providing timely and accurate administrative management of work hours, sales call data, customer objectives, communication responses, synchronization, sample and expense reporting.
  • Expected to meet or exceed all NSR deliverables.
  • Effectively create and build a compliant business plan based on depth and breadth of customer business needs, resources and products.
  • Complete all company and job-related training as assigned within the required timelines.
  • Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
Desired Qualifications
  • Pharmaceuticals, biologics, and/or medical device sales experience preferred
  • Antipsychotic sales experience is a plus
  • Experience in telemedicine/virtual environment adaptation may be considered desirable

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.